Can a new pill help slow lung changes in people with family risk?
Treatments studied
Part of Lungs & breathing clinical trials.
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 40 years old or older.
- You must have a parent, sibling, or child who has been diagnosed with a type of lung scarring (pulmonary fibrosis).
- A CT scan of your lungs must show early signs of lung changes (at least 5% of one lung area affected).
- Your lung function tests must be relatively good: a breathing test (FVC) at least 80% of normal, and a gas exchange test (DLCO) at least 70% of normal.
- You cannot have a pattern of more advanced scarring (called usual interstitial pneumonia) on your CT scan.
- You cannot have taken the study drug (nerandomilast) or other fibrosis medications (nintedanib or pirfenidone) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
This study looks at what causes familial (inherited) pulmonary fibrosis by studying relatives who are not yet diagnosed with the lung disease. You may help researchers understand risk and early changes in the lungs within families.
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
This trial tests whether combining two medications—nerandomilast (a new anti-inflammatory drug) and mycophenolate (an immunosuppressant you may already be taking)—can safely slow lung scarring in people with pulmonary fibrosis other than IPF. The goal is to help doctors decide if this combination is right for you.
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
Hear when a new Familial Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.